tirzepatide surmount-1 nejm 2022 weight loss percent (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants GLP-1 Medications for Weight Loss:

Patients with lower-responding variants benefit from earlier dose escalation or dual-compound therapy (GLP-Squared), while high-responders may sustain progress longer at standard doses

However, it is important to note that analyzing clinical differences using spontaneous reporting system databases presents inherent challenges due to confounding factors

Moon et al suggested a hypothesis that GLP-1 Thr 13 interacts with a binding pocket formed by Ile 196 , Leu 232 , and Met 233 of GLP-1R because Thr 7 -containing chimeric peptides are highly sensitive for the Ile 196 mutation

Both responses are normal

Its taken once or twice a day, up to a maximum dose of 2 tablets, twice a day

There could be something else going on